Global antibiotics market value was USD 40.7 billion in 2020. It is expected to grow at a compound annual rate (CAGR of 4.5%) between 2021 and 2028. Market drivers include the rising incidence of infectious diseases and the support provided by government legislation. The market will also be affected by an increase in antibiotic resistance due to overuse or misuse of antibiotics. This could lead to new therapies being prescribed to treat bacterial infections. The CDC estimates that more than 2.8 million people in America are suffering from antibiotic-resistant infection. In developed countries, the resistance rate for pathogens like Enterobacteriaceae and P. aeruginosa is an average 40%.
Market growth is expected to be driven by the increased efforts of pharmaceutical companies to develop novel treatments for infectious diseases. Pew Charitable Trust reported that 41 promising molecules were under investigation for treatment of severe bacterial infections in December 2019. 17 of these investigational drugs are currently in the third stage of clinical trials, while the other 17 have submitted NDAs for approval. They are expected to be commercialized over the forecast period. Four new antibiotic drugs were approved by the U.S. FDA in the second half 2019. Additionally, the GAIN Act (and the REVAMP Act) are expected to accelerate the global approval process. Over the forecast period, the market will grow due to the launch of new antibiotic medicines.
Due to an increase in the incidence of infectious diseases, there is a significant rise in demand for antibiotics. Market growth is also fueled by the high incidence of infectious diseases such as pneumonia, malaria, and lower respiratory infections. The increasing disease burden has prompted both government and non-government entities to invest in R&D initiatives. This will help to develop novel antibiotics, and support regulatory policies that will speed up the approval process. BARDA, in partnership with the government, has extended its support for several companies to help develop new treatments for infectious diseases.
Collaborations in the development and production of antibiotics will likely result in the creation of many new antibiotic drugs over the next few years. To reduce the costs of drug development, pharmaceutical companies have begun to collaborate with each other. Nosopharm, for example, announced a partnership with Evotec AG in July 2019 to develop NOSO-502. It is a novel antibiotic that fights Enterobacteriaceae infection. In April 2019, Forge Therapeutics, Inc., and Basilea Pharmaceutica Ltd. announced an agreement for research collaboration and a license agreement to create novel antibiotics.
The product pipeline will be boosted by the growing number of public-private partnerships, in which funding and innovative R&D approaches for antibiotic development are provided to public agencies. In March 2019, for example, the Global Antibiotic Research and Development Partnership announced a public-private partnership between Evotec AG and Evotec AG to develop first-in-class antibiotics that can be used to treat drug-resistant bacterial infection.
With a market share of 52.1% in 2020, cell wall synthesis inhibitors were the dominant players and will continue to be so throughout the forecast period. The key drivers of this segment are high consumption according to prescription and substantial government funding. Cell wall synthesis inhibitors are one of the most popular antibiotics because they have broad spectrum action against both gram-positive as well as negative bacteria. Due to increased research and government funding, cell wall synthesis inhibitors will see significant growth in the future. Bicycle Therapeutics, for example, announced in February 2019 the development of a novel cell-wall synthesis inhibitor after it received a grant from the U.K.
Due to increased product launches and R&D efforts, the RNA synthesis inhibitors market segment will experience significant growth. Cosmo Pharmaceuticals N.V. launched Aemcolo (rifamycin), an extended-release tablet for the treatment and prevention of Travelers' Diarrhea. The U.S. FDA also granted Fast Track and Qualified Infectious Drug Product (QIDP), designations for the product, as well as marketing exclusivity until 2028.
Penicillin was the most popular drug in 2020, representing 23.9% of the total market. This is due to its high prescription rate and large number of generic producers. These drugs are the first choice for treating infections such as pharyngitis and skin infections, bronchitis and gonorrhea. Cephalosporin was the second-largest segment of drug classes after Penicillin. It is expected to continue growing at a rapid pace during the forecast period.
Between 2021 and 2028, the cephalosporin-fluoroquinolone segment is expected to grow at an impressive rate. These segments will grow due to the commercialization and distribution of new drugs in the forecast period. Three cephalosporin drugs are currently in the third phase clinical trials. They are expected to be commercialized in the next three to four years. Market share will increase due to the U.S. FDA approval in November 2019 of Shionogi’s Fetroja (cefiderocol). The growth of fluoroquinolones will be accelerated by the Japan PMDA approval of Lasvic (lascufloxacin), and Wockhardt Ltd.'s new Indian drug application submission.
Because of the upcoming launch of new therapies, the others segment will grow the fastest in the future. This includes both existing antibiotics and some newer ones, including tetracyclines. Market growth is expected to be boosted by the commercialization of zoliflodacin and gepotidacin during the forecast period.
Asia Pacific accounted for 45.2% of the global market in 2020. It is expected to experience significant growth over the forecast period. This is due to high antibiotic consumption, an increase in infectious diseases and government initiatives to develop new therapies to combat drug-resistant infections. The growth of the region's market is also being aided by the existence of generic players. The largest markets for antibiotics within the region are India and China. These countries are key drivers of market growth because they have unregulated sales and high consumption of antibiotics.
North America was the second largest regional market for antibiotics, after Europe. Together, North America and Europe held 48.0% of the antibiotics market in 2020. These markets have a well-developed healthcare infrastructure and are tightly regulated. North American markets are driven by rising rates of infectious diseases and increasing government healthcare spending. The U.S. government has taken a variety of measures to combat infectious diseases, such as promoting R&D and antibiotic stewardship.
These companies are involved in the development and marketing of new therapies. They also market products that target bacterial resistance mechanisms. Other companies include those that have clinical-stage assets and are expected to enter the market in the near future. The following are some of the most prominent players in global antibiotics markets:
Merck & Co., Inc.
Allergan plc (AbbVie)
GlaxoSmithKline plc.
Pfizer Inc.
Melinta Therapeutics
Basilea Pharmaceutica Ltd.
Tetraphase Pharmaceuticals
Paratek Pharmaceuticals, Inc.
Nabriva Therapeutics plc
Spero Therapeutics
Up Market Research published a new report titled “Antibiotics Market research report which is segmented by Drug Class (Penicillin, 7-ACA, Cephalosporin, Aminoglycoside, Fluoroquinolone, Macrolide, Sulfonamide, Carbapenem), By Players/Companies GlaxoSmithKline plc, Merck & Co Inc, Tetraphase Pharmaceuticals, Nabriva Therapeutics plc, Melinta Therapeutics, Spero Therapeutics, Paratek Pharmaceuticals Inc, Basilea Pharmaceutica Ltd, Allergan plc (AbbVie), Pfizer Inc”. As per the study the market is expected to grow at a CAGR of XX% in the forecast period.
Report Attributes | Report Details |
Report Title | Antibiotics Market Research Report |
By Drug Class | Penicillin, 7-ACA, Cephalosporin, Aminoglycoside, Fluoroquinolone, Macrolide, Sulfonamide, Carbapenem |
By Companies | GlaxoSmithKline plc, Merck & Co Inc, Tetraphase Pharmaceuticals, Nabriva Therapeutics plc, Melinta Therapeutics, Spero Therapeutics, Paratek Pharmaceuticals Inc, Basilea Pharmaceutica Ltd, Allergan plc (AbbVie), Pfizer Inc |
Regions Covered | North America, Europe, APAC, Latin America, MEA |
Base Year | 2020 |
Historical Year | 2018 to 2019 (Data from 2010 can be provided as per availability) |
Forecast Year | 2028 |
Number of Pages | 246 |
Number of Tables & Figures | 173 |
Customization Available | Yes, the report can be customized as per your need. |
The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include products, applications, and competitor analysis.
The market is segmented by Drug Class (Penicillin, 7-ACA, Cephalosporin, Aminoglycoside, Fluoroquinolone, Macrolide, Sulfonamide, Carbapenem).
Antibiotics Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report.
Key Benefits for Industry Participants & Stakeholders:
Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa (MEA). North America region is further bifurcated into countries such as U.S., and Canada. The Europe region is further categorized into U.K., France, Germany, Italy, Spain, Russia, and Rest of Europe. Asia Pacific is further segmented into China, Japan, South Korea, India, Australia, South East Asia, and Rest of Asia Pacific. Latin America region is further segmented into Brazil, Mexico, and Rest of Latin America, and the MEA region is further divided into GCC, Turkey, South Africa, and Rest of MEA.
We have studied the Antibiotics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2028.
How you may use our products:
Reasons to Purchase the Antibiotics Market Report:
Some other reports from this category!